IMVT
Immunovant, Inc.26.61
+0.61+2.35%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
Q&A adds brepo CS Phase III color
Q&A largely reaffirmed the blockbuster Phase II brepocitinib results in cutaneous sarcoidosis, explaining baseline imbalances that made the 45mg arm tougher yet still dominant on stringent endpoints. Management shared pricing bookends between IVIG (~$180k) and VYVGART (~$870k gross), eyed 45mg for a DM-sized Phase III pending FDA input, and pegged CS at ~40,000 patients, smaller than dermatomyositis. Efficacy offers big erosion cushion. No walk-backs; analysts' Phase III, RA, and BD probes drew measured replies stressing internal priorities first. Pipeline excitement intact. Brepo's CS data cushions Phase III risks.
Key Stats
Market Cap
5.36BP/E (TTM)
-Basic EPS (TTM)
-2.82Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Immunovant posted a Q3 FY2026 net loss of $110.6M, nearly flat y/y from $111.1M despite steady $114.4M operating expenses, thanks to $5.3M interest income. R&D ticked up 4.7% y/y to $98.9M on IMVT-1402 trials in endocrine (+28% y/y) and rheumatology (+109% y/y), offset by lower neuro spend; YTD net loss widened to $357.8M from $307.4M on 15% higher opex. Cash swelled to $994.5M (up from $714.0M at FY start) via December's $543.6M offering; operating cash burn hit $312.3M YTD. No debt. Shares outstanding jumped to 203.3M. Diluted EPS aligns with anti-dilution from losses. HanAll license dispute looms.
8-K
Q3 loss steady, cash surges
8-K
Immunovant prices $550M offering
Immunovant priced a $550 million common stock offering on December 10, 2025, backed by controlling shareholder Roivant, set to close around December 12. Combined with existing cash, proceeds fund operations through IMVT-1402's potential Graves' Disease launch. Clinical trials face delays from enrollment hurdles. HanAll disputes loom over batoclimab rights.
8-K
CMO Geffner exits Immunovant
Immunovant restructured R&D leadership, with Chief Medical Officer Michael Geffner, M.D., M.B.A., departing effective November 21, 2025. He receives severance per his prior agreement and will consult through April 30, 2026, with equity vesting continued during that period. Leadership shakeup streamlines operations under CEO Eric Venker.
ALT
Altimmune, Inc.
5.03-0.25
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
DNTH
Dianthus Therapeutics, Inc.
41.40-0.52
IMA
ImageneBio, Inc.
6.25+0.08
IMNN
Imunon, Inc.
3.88-0.09
IMTX
Immatics N.V.
10.09+0.11
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
IMUX
Immunic, Inc.
0.60-0.01
PVCT
Provectus Biopharmaceuticals, I
0.06+0.00
ROIV
Roivant Sciences Ltd.
22.94+1.04